Publications by authors named "Gerald Prager"

Claim this Profile
P
Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE.
Karin Potthoff, Jens Uhlig, Lutz Jacobasch, Lothar Müller, Marcel Reiser, Gerald Prager

Int J Cancer· February 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opportunities and Approaches to Optimising Advanced Cholangiocarcinoma Outcomes in the Era of Targeted Therapies: A Narrative Review.
Teresa Macarulla, Cindy Neuzillet, Gerald W Prager, Lorenza Rimassa, John Bridgewater

Oncol Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers.
Margherita Rimini, Lorenzo Fornaro, Masafumi Ikeda, Oluseyi Abidoye, Jessica Lucchetti, Gerald W Prager

Liver Int· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population.
Federica Lo Prinzi, Francesca Salani, Silvia Camera, Mario Domenico Rizzato, Anna Saborowski, Gerald W Prager

Int J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors for very early recurrence after neoadjuvant treatment and curative resection in pancreatic ductal adenocarcinoma.
Carl-Stephan Leonhardt, Klaudia Narbekovas, Motaz Qadan, Klaus Sahora, Andrew L Warshaw, Gerald Prager

Surgery· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab.
Chiara Pirrone, Umberto Malapelle, Francesco Pepe, Federica Lo Prinzi, Federico Nichetti, Gerald W Prager

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAF-mutated metastatic colorectal cancer according to primary tumor sidedness: A pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group).
Lena Weiss, Sebastian Stintzing, Dominik Paul Modest, Arndt Stahler, Ludwig Fischer von Weikersthal, Gerald Werner Prager

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population.
Margherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, Mario Domenico Rizzato, Anna Saborowski, Gerald W Prager

J Natl Cancer Inst· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study.
Margherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi, Mario Domenico Rizzato, Anna Saborowski, Gerald W Prager

Int J Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial.
Julien Taieb, Dominik P Modest, Marwan Fakih, Fortunato Ciardiello, Eric Van Cutsem, Gerald W Prager

Eur J Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of antibiotic therapy in patients with cholangiocarcinoma treated with chemoimmunotherapy.
Francesco Vitiello, Caterina Vivaldi, Mario Domenico Rizzato, Anna Saborowski, Lorenzo Antonuzzo, Gerald W Prager

Oncology· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lack of association between prior or concurrent malignancies and overall survival in gastroesophageal cancer: evidence from a large European single-center cohort.
Hannah C Puhr, Luzia Berchtold, Linda Zingerle, Martin Korpan, Julia M Berger, Gerald W Prager

Clin Transl Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumor DNA (ctDNA) trajectories predict survival in trifluridine/tipiracil-treated metastatic colorectal cancer patients.
Matthias Unseld, Stefan Kühberger, Ricarda Graf, Christine Beichler, Markus Braun, Gerald W Prager

Mol Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC-D Index.
Mara Persano, Margherita Rimini, Francesca Salani, Federica Lo Prinzi, Federico Nichetti, Gerald W Prager

Liver Int· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Treatment With Trifluridine/Tipiracil in Combination With Bevacizumab on Health-Related Quality of Life and Performance Status in Refractory Metastatic Colorectal Cancer: An Analysis of the Phase III SUNLIGHT Trial.
Julien Taieb, Marwan Fakih, Josep Tabernero, Fortunato Ciardiello, Eric Van Cutsem, Gerald W Prager

Clin Colorectal Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of family history with patient characteristics and prognosis in a large European gastroesophageal cancer cohort.
Hannah C Puhr, Luzia Berchtold, Linda Zingerle, Melanie Felfernig, Lisa Weissenbacher, Gerald W Prager

Wien Klin Wochenschr· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction to: Association of family history with patient characteristics and prognosis in a large European gastroesophageal cancer cohort.
Hannah C Puhr, Luzia Berchtold, Linda Zingerle, Melanie Felfernig, Lisa Weissenbacher, Gerald W Prager

Wien Klin Wochenschr· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline Liquid Biopsy in Relation to Tissue-Based Parameters in Metastatic Colorectal Cancer: Results From the Randomized FIRE-4 (AIO-KRK-0114) Study.
Sebastian Stintzing, Susanne Klein-Scory, Ludwig Fischer von Weikersthal, Martin Fuchs, Florian Kaiser, Gerald Prager

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population.
Federica Lo Prinzi, Francesca Salani, Margherita Rimini, Mario Domenico Rizzato, Lorenzo Antonuzzo, Gerald W Prager

Oncologist· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The myth of a cancer-specific temperament: An analysis of affective temperament in cancer patients.
Elisabeth L Zeilinger, Matthias Knefel, Andreas Erfurth, Denise Andrzejewski, Otto Lesch, Gerald Prager

J Psychosom Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer.
Julien Taieb, Marwan Fakih, Gabor Liposits, Gerald W Prager, Eric Van Cutsem

Front Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current Landscape of Molecular Biomarkers in Gastroesophageal Tumors and Potential Strategies for Co-Expression Patterns.
Martin Korpan, Hannah Christina Puhr, Julia M Berger, Alexander Friedrich, Gerald W Prager

Cancers (Basel)· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evidence-based cancer care: assessing guideline adherence of multidisciplinary tumor board recommendations for breast and colorectal cancer in a non-academic medical center.
Carl-Stephan Leonhardt, Leopold Lanzenberger, Raphael Puehringer, Ulla Klaiber, Irene Hauser, Gerald Prager

J Cancer Res Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer.
Thierry André, Eric Van Cutsem, Julien Taieb, Marwan Fakih, Gerald W Prager

Curr Treat Options Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data.
Patrick Reimann, Ilektra-Antonia Mavroeidi, Jonathan Burghofer, Hossein Taghizadeh, Gerald Webersinke, Gerald W Prager

Cancer Immunol Immunother· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis